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Abstract: 
The aim of this study was to evaluate the choice of polymer and polymer level on the 
performance of the microstructure and wettability of hot-melt extruded solid dispersion of 
Glyburide (Gly) as a model drug. The produced solid dispersion were characterised using 
scanning electron microscopy (SEM), image analysis using a focus variation instrument 
(FVI), differential scanning calorimetry (DSC), X-ray powder diffraction (XRPD), X-ray 
microtomography (XµT), dynamic contact angle measurement and dissolution analysis using 
biorelevant dissolution media (FASSIF). SEM and focus variation analysis showed that the 
microstructure and surface morphology was significantly different between samples 
produced. This was confirmed by further analysis using XµT which showed an increase in 
polymer content brought about a decrease in porosity of the hot-melt extruded dispersions. 
DSC suggested complete amorphorisation of Gly whereas XRPD suggested incomplete 
amorphorisation. The static and dynamic contact angle measurement correlated with the 
dissolution studies using FASSIF media indicating that the initial liquid imbibition process as 
captured by the dynamic contact angle directly affects the dissolution performance.  
 
Keywords: solid dispersion; glyburide; hot-melt extrusion; contact angle, Soluplus®; 
Kollidon

 VA64 
Abbreviations: Gly, glibenclamide or glyburide; DSC, differential scanning calorimetry; 
XRPD, x-ray powder diffraction; API, active pharmaceutical ingredient; BCS, 
biopharmaceutical classification system; SOL, Soluplus
®
; XµT, x-ray microtomography; 
FASSIF, fasted simulated intestinal fluid; ASD, amorphous solid dispersions; Kollidon
®
 
VA64 or PVP VA64,  polyvinylpyrrolidone-vinyl acetate copolymer; DE, dissolution 
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efficiency; MDT, mean dissolution time; FVI, focus variation instrument; SEM, scanning 
electron microscopy; HME, hot-melt extrusion 
 
1. Introduction:  
The utilising of innovative combinatorial chemistry and high-throughput screening tools in 
drug discovery has led to more active pharmaceutical ingredients with poorly soluble 
properties reaching clinical stages of drug development processes. It is estimated that two out 
of five pharmaceutical compounds in the US market are considered poorly soluble (Fahr and 
Liu, 2007). Poorly soluble drugs are very challenging during pharmaceutical development as 
solubility, and further dissolution tends to be the rate-limiting step for these compounds 
entering the systemic circulations and giving the desired therapeutic response (Adebisi et al., 
2016; Conway and Asare-Addo 2016). To overcome this challenge, several techniques are 
used. These techniques can be classified into two main categories (Savjani et al., 2012). I: 
physical modification such as particle size reduction, optimisation of microstructure, 
supercritical fluids or crystal habit (polymorphs and amorphous forms) II: Chemical 
modification such as salt formation and co-crystals., use of buffers or novel excipients 
(Adebisi et al., 2016; Al-Hamidi et al., 2015, 2013, 2010a, 2010b; Asare-Addo et al., 2018; 
Guillory, 2003; He et al., 2017; Nokhodchi et al., 2017; Rabinow, 2004; Ramirez et al., 2017; 
Stahl and Wermuth, 2018; Šupuk et al., 2013)  
Each technique has its drawbacks. For example, the enhancement of solubility of a neutral, 
weakly acidic or weakly basic drug using salt formation is not always feasible. Reducing the 
size can also be limited as generating very fine particles can pose safety issues during 
handling (Vasconcelos et al., 2007; Serajuddin, 1999). One of the attractive routes to 
overcoming these problems is by manufacturing amorphous solid dispersions (ASD). ASD 
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systems are composed of amorphous drug stabilised by the presence of a polymer (Newman 
et al., 2015). Solid dispersions can be manufactured by either solvent evaporation techniques 
or melting methods. In the solvent evaporation technique the drug and polymer are dissolved 
in a solvent followed by the evaporation of the solvent using spray drying (Ali and 
Lamprecht 2017; Sawicki et al., 2016; Paudel et al., 2013) or freeze drying methods (Pas et 
al., 2018; Lian et al., 2014; Betageri and Makarla, 1995). Melting methods, especially hot-
melt extrusion (HME) have many advantages including scalability, being a solvent and dust 
free method and has industrial applicability (Paudel et al., 2013). The drug-polymer is 
blended then fed through a hopper to a heated barrel of a twin screw extruder. In the extruder, 
the drug-polymer blend experiences very high shear and temperature which leads to the 
formation of a homogenous dispersion of the drug into the polymer matrix. The formed solid 
dispersion is then pushed through the die to get the solid dispersion threads which are then 
subjected to pelletisation and the pellets collected as a finished product. The physical 
properties and ultimately the performance of pellets can be controlled by either changing the 
processing parameters such as temperature, speed or twin-screw configuration or using 
different polymers (Van den Mooter, 2012).   
Polyethyleneglycol–polyvinyl caprolactam–polyvinyl acetate grafted copolymer 
(PEG6000/vinylcaprolactam/vinyl acetate copolymer, Soluplus
®
, BASF, Germany) (Figure 
1) is a promising polymer that has attracted a lot of attention over the last decade. Soluplus
®
 
possesses the advantages of improving both the process (Djuris et al., 2013) and the 
dissolution rate of poorly soluble drugs (Nagy et al., 2012). The addition of PEG 6000 and 
the low glass transition temperature enhances the processability and eliminates the need of a 
plasticiser. Soluplus
®
 also improves the dissolution rates of poorly soluble drugs by forming 
a solid solution with the drug. Kollidon® VA64 or PVP VA64 (polyvinylpyrrolidone-vinyl 
acetate copolymer) (Figure 1) is another polymer which has been demonstrated to enhance 
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the dissolution rate of poorly soluble drugs (Ponnammal et al., 2018). PVP VA64 works by 
solubilising poorly soluble drugs and ultimately improving the dissolution rate. An 
enhancement in mechanical properties and the production of flexible extruded pellets has 
been reported for the use of PVP VA64 (Solanki et al., 2018). Both polymers are considered 
as safe excipients and easy to handle with good flowability properties (Djuris et al., 2013; 
Nagy et al., 2012). 
Glyburide (Gly), used as a model drug, is an example of a poorly soluble weak acidic drug 
(Figure 1) with an estimated pKa of 5.3 (Löbenberg et al., 2000). The acidic properties of the 
drug and its pKa value suggests that the drug will be favourably absorbed in the upper 
intestine. Wei et al studied the solubility of Gly in biorelevant dissolution media and found 
that the solubility of Gly in biorelevant media increased as pH increased. FASSIF media at 
pH 7.4 had the highest solubility (Wei and Löbenberg, 2006). The objectives of this research 
was to prepare and characterise solid dispersion of Gly using Soluplus
®
 (Sol) and PVP VA64 
at two different polymer levels. It was therefore the aim of the authors to characterise the 
surface of the pellets using a focus variation instrument and to determine the effect polymer 
type and polymer level on wettability. The authors also investigated a correlation of the 
wettability of the solid dispersions (polymer level and type) with the performance of 
dissolution as to the best of our knowledge, there are no research articles that have studied 
this.   
2. Materials and Methods 
2.1. Materials 
Poly (N-vinyl caprolactam)–poly (vinyl acetate)–poly (ethylene glycol) (57:30:13), under the 
trade name Soluplus® and polyvinylpyrrolidone-vinyl acetate copolymers branded as 
Kollidon

 VA 64 were kind gifts from BASF (Germany). Gly was purchased from 
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Kemprotec (Cumbria, U.K.). FASSIF (fasted simulated intestinal fluid) powder was 
purchased from Biorelevant Ltd (Surrey, United Kingdom). PEG4000 was purchased from 
Sigma Aldrich (UK).  Monobasic potassium phosphate, sodium hydroxide, ammonium 
acetate, acetic acid and acetonitrile were all purchased from Sigma Aldrich, UK. All 
materials were of analytical grade and used as obtained. 
 
2.2. Preparation of hot-melt extruded (HME) solid dispersions 
A 16 mm twin screw extruder (Pharmalab, Thermo Scientific, UK) was used to carry out the 
extrusion work. Gly and either PVP VA64 or Soluplus
®
 at two different ratios (1:1 and 1:2) 
were mixed using a T2F Turbula Blender System (Willy A Bachofen AG) for 10 min in order 
to ensure uniformity of powder mixing. PEG 4000 was added to the PVP VA64 samples as a 
plasticiser and to improve the process of extrusion. Each powder mixture was then extruded 
using the hot-melt extruder. A maximum barrel temperature of 175 

C was used to ensure 
that the Gly was completely melted (melting point of Gly is 175 

C) (Betageri and Makarla, 
1996) (The configuration for the HME was a mixture of conveying and kneading 
elements with a stagger angle of 60 degrees for the kneading elements. The screw 
rotation speed was set at 100 rpm for all four sample batches. The temperatures of the 
nine heated barrel and die zones were set as shown in supplementary materials Table 
S1. The feeding rate of the powder was set at 5 g/min). Care was taken to ensure the 
degradation temperature of Gly which has been reported to range between 195 - 200 

C 
(Wei et al., 2008) was not reached by reading the actual temperature recorded during 
the HME process also. The produced pellets were separated into two sub samples: the first 
samples were characterised as received from the HME process using SEM, a focus variation 
instrument and X-ray computed microtomography (XμT) to get an insight into the 
microstructure and its potential impact on dissolution. The second sample (pellets) were 
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further milled using a mortar and pestle and sieved to 250 µm undersize (to ensure the 
same size fractions were used) for all the samples (all the milled samples were further 
analysed using a Laser diffraction instrument (Sympatec, UK) to further confirm the 
particle size distribution) and characterised using DSC and XRPD to check the changes in 
the crystallinity of Gly. The latter samples were used in the dissolution testing and labelled as 
samples A-D (Sample A is 1:1 Gly:Sol, Sample B is 1:2 Gly:Sol, Sample C is 1:1 Gly:PVP 
VA 64 and Sample D is 1:2 Gly:PVP VA 64) and their corresponding physical mixtures 
labelled as samples PMA-PMD. All samples were stored in a desiccator prior to use to 
decrease the potential effect of hygroscopicity.  
 
2.2.2 Content uniformity of Gly in milled and sieved samples 
50 mg of the milled and sieved samples A-D were dissolved each in 50 mL acetonitrile and 
an assay was performed  to determine the Gly content using the HPLC method as explained 
in section 2.6.3. The results from the assay were further used to determine the amount of 
powder needed to fill the gelatine capsules size 3 to ensure the same amount of Gly was 
present in each capsule.  
 
2.3. Solid State characterisation:  
2.3.1. Scanning electron microscopy (SEM) and image analysis using a focus variation 
instrument 
A scanning electron microscope (Jeol JSM-6060CV SEM) operating at 10 kV was used to 
generate electron micrographs images. Pellets (Samples A-D) were cross-sectioned and 
mounted onto a metal stub using a double-sided adhesive tape. Samples were then sputter-
coated with gold for 60 s using a Quorum SC7620. Micrographs with different 
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magnifications were taken to aid an understanding of the polymer ratios impact on the pellets 
produced.  
A focus variation instrument (Contour LS 3D Optical Profiler (Bruker)) was used to assess 
the surface topography of the pellets using 10 x objective and 2.9 μm lateral resolution. The 
obtained images were further analysed using the Surfstand™ software (Taylor Hobson, UK, 
and University of Huddersfield, UK) to obtain 2D and 3D profiles of the surfaces (Ward et 
al., 2017). The Sq parameter which is defined as the root mean square value of the surface 
departures from the mean plane within the sampling area was of interest with regards to the 
influence of the polymer concentration on the pellets produced. This parameter is represented 
by equation 1: 
     
 
 
           
 
                                                                                            Equation 
1 
Where: 
A = Sampling Area 
Z(x,y) = surface departures 
2.3.2. Differential scanning calorimetry (DSC) 
Thermal studies for the milled samples and their corresponding physical mixture were 
investigated using the software obtained from Mettler-Toledo, Switzerland. 3-6 mg of the 
milled and seived samples (Samples A-D) or its physical mixture (Samples PMA-PMD) was 
placed in a standard aluminium pan with a vented lid and sealed. The crimped pans were 
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heated from 20 to 250 °C at a scanning rate of 10 °C/min using nitrogen gas to purge the 
DSC (Mettler-Toledo, Switzerland).  
2.3.3. X-ray powder diffraction (XRPD) 
Gly, the milled and sieved powder (Samples A-D) and their corresponding physical mixtures 
(Samples PMA-PMD) were scanned using Bragg–Brentano geometry, over a scattering 
(Bragg, 2θ) angle range from 5 to 100°, in 0.02° steps at 1.5° min−1 using a D2 Phaser 
diffractometer (Bruker AXS GmbH, Karlsruhe, Germany) (Laity et al., 2015). The XRPD 
signals were further analysed using Microsoft Excel.  
2.4. X-ray microtomography (XµT) 
Pellets (as obtained from section 2.2) were imaged by XμT (Nikon XT H 225, Nikon Corp. 
Tokyo, Japan) using a tungsten target with 75 kV accelerating voltage and 250 μA gun 
current using a copper filter (thickness 0.125 mm). Pellets were mounted using a double-
adhesive tape. A set of projections were collected with over 120 min XμT acquisition. The 
set of projection images were then reconstructed using CT-Pro and then examined using VG 
Studio 2.1 software.  
 
2.5. Dynamic contact angle measurement  
The sessile drop method (Drop Shape Analysis System, DSA30, Krüss GmbH, Hamburg, 
Germany) was used to obtain the dynamic contact angle for each formulation (Figure 2) 
(contact angle testing was conducted for the milled and sieved samples only – samples 
A-D). This was performed using 1 µL either of deionised water or a FASSIF medium. The 
liquid was dispensed from a needle to generate a drop and images of the droplet were 
recorded with a rate of 10 frames per second. The measurements were made at room 
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temperature in triplicate and the average values and standard deviations were calculated. The 
initial contact angle was determined from the first ten images (measurement time of 1 s).  
2.6. Dissolution analysis 
2.6.1 Media preparation: 
Biorelevant dissolution media was prepared by dissolving 2.24 g of FASSIF powder for each   
1 L of phosphate buffer (pH 7.4). The biorelevant dissolution media was further left under 
stirring conditions for 2 h. The phosphate buffer was prepared using monobasic potassium 
phosphate and sodium hydroxide according to the USP pharmacopoeia (Wei and Obenberg, 
2006). 
2.6.2. Dissolution of the Gly solid dispersions: 
A USP I (basket method) apparatus was used for the dissolution testing. 900 mL of 
dissolution media (section 2.6.1) was filled in a 1L dissolution vessel. The media was heated 
to 37  0.5 °C. The physical mixtures (PMA-PMD) as well as the milled and sieved powder 
samples (samples A-D) containing an  equivalent of 20 mg Gly content (based on their 
content uniformity –section 2.2.2) were weighed and then used to fill a size 3 hard gelatine 
capsule before being transferred to the basket. A rotation speed of 100 rpm was used. The 
dissolution study was conducted for 2 h. 10 mL of the dissolution media was withdrawn and 
filtered at the 1, 5, 10, 20, 30, 45, 60, 90 and 120 min predetermined time points for HPLC 
analysis of Gly content. A preheated biorelevant media was used to replace the 10 mL media 
taken out after each time point to ensure the constant 900 mL volume. All dissolution studies 
were conducted in triplicate.  
2.6.3. HPLC analysis: 
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A Shimadzu HPLC system equipped with a C18 column (250 mm x 4.6 mm ID, 4μm, 
Phenomenex) was used for the Gly analysis. An Isocratic elusion type with a mobile phase of 
ammonium acetate and acetonitrile (45:55) was used at a flow rate of 1 mL/min.  A UV-Vis 
detector was utilised, and the absorption peak for Gly was investigated at a maximum 
wavelength of 254 nm. The retention time for Gly was around 2.8 min (Gedeon et al., 2008)  
2.6.4. Dissolution parameters 
Mean dissolution time (MDT) (Equation 2), defined as the mean time for the drug to dissolve 
under in-vitro dissolution conditions, is a model-independent method and is suitable for 
dosage forms that have different mechanisms of drug release (Al-Hamidi et al., 2013; Kaialy 
et al., 2016; Khan, 1975; Mu et al., 2003; Nep et al., 2017)  
    
       
 
   
    
 
   
,               Equation 2 
where j is the sample number, n is the number of dissolution sample times,    is the time at 
midpoint between    and      and      is the additional amount of drug dissolved between    
and     . 
The dissolution efficiency (DE) (Equation 3) is defined as the area under the dissolution 
curve up to a certain time t, expressed as a percentage of the area of a rectangle described by 
100% dissolution in the same time t (Asare-Addo et al., 2015; Khan, 1975) was also 
calculated.  
   
     
 
 
      
    ,          Equation 3 
where y is the drug percent dissolved as a function of time t. 
3. RESULTS AND DISCUSSION 
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3.1. Solid-state analysis 
The thermal analysis of Gly, the milled and sieved products (Samples A-D) and their 
corresponding physical mixtures (Samples PMA-PMD) are depicted in Figure 3. DSC 
showed Gly to have a sharp melting point of 175 °C confirming its crystallinity. This was 
similar to the work published by Cirri et al. (Cirri et al., 2004) who reported Gly to have a 
sharp melting point at around 175 °C. The physical mixtures of Gly with both Sol and PVP 
VA64 showed a similar peak at the melting point of Gly but with less intensity. It was also 
interesting to note that an increase in the polymer content brought about a general reduction 
in the melting point of Gly. This behaviour can be attributed to the increased drug 
polymer interaction with increase polymer content. The increased interactions can 
cause a melting point depression due to the increase in hydrogen bonding interactions 
between the drug and polymer (Huang and Dai, 2014; Rim and Runt, 1984). The 
physical mixture of Gly with PVP VA64 showed another peak at around 60 °C. This 
corresponds to the melting point of PEG4000 which was added to the formulations as a 
plasticiser (Sheskey et al., 2017). The resultant extruded products of Gly:Sol and Gly:PVP 
VA64 at the two drug loading levels showed no obvious melting point peak for Gly thereby 
suggesting that Gly had been molecularly dispersed within the polymers used (Figure 3). 
XRPD confirmed Gly to be completely crystalline in the pure form (Figure 4). Upon 
inclusion with Sol or PVP VA64 through the HME process, there was a significant reduction 
in the crystallinity of Gly. It was observed that an increase in the polymer content brought 
about a further decrease in the crystallinity of Gly. Interestingly, the XRPD data did reveal 
that samples A-D were not fully amorphous as suggested from the DSC data (Figure 4). 
Samples A and B however were observed to be more amorphous than C and D suggesting 
that with the process parameters used for the HME processing, Sol had the greater ability in 
converting crystalline Gly to its amorphous form which may potentially have implications for 
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dissolution testing. The amorphorised regions embedded in the two polymers also 
suggests that a further manipulation of several processing parameters such as screw 
speed, screw configuration, feed rate and temperature could impact on the drive 
towards full amorphorisation. 
3.2. SEM and focus variation analysis 
SEM images of the HME pellets, the physical mixtures as well as the milled and sieved 
fractions of the HME pellets are shown in Figure 5. Gly is crystalline in nature with 
irregularly shaped particles (Wei et al., 2008). The microstructure of the pellets vary in terms 
of its overall porosity (further analysed using XµT). Upon magnification, some of the 
crystalline drug could be seen on the surfaces of some extrudates (highlighted by yellow 
dashed circles) confirming the XRPD analysis that Gly had not been fully molecularly 
dispersed into the polymers (Figure 5). This was however not evident on the samples with 
increased polymer content (Samples B and D).  
The images produced from focus variation measurement highlighted significant surface 
texture across all four extrudes in keeping with SEM (Figure 6). This was indicated by the 
deep valleys across the x profile (Supplementary material S1). The Sq parameter can be 
viewed as a measure the vertical scale of the surface. Analysis of the data showed that an 
increase in polymer content for the extrudates brought about an increase in the Sq value 
(Sample A, 1:1 Gly:Sol – Sq = 19.83 µm ;  Sample B, 1:2 Gly:Sol – Sq = 48.78 µm; Sample 
C, 1:1 Gly:PVP VA64 – Sq = 26.56 µm; Sample D, 1:2 Gly:PVP VA64 – Sq = 33.58 µm).   
3.3. X-ray computed microtomography 
The reconstructed XµT cross-sectional images of filaments indicate differences in the 
microstructure of these filaments confirming the results from SEM (Figure 7). The higher the 
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electron density of the material, the stronger it absorbs X-rays and hence the intensity values 
in the XµT images are higher (brighter) (Bentz et al., 2000; Stock, 1999). Sample A (1:1 
Gly:Sol) showed a higher porosity (63.72 %) compared to sample B (1:2 Gly:Sol) (57.41 %) 
suggesting that an increase in the Sol content brought about a decrease in the porosity 
(converted as a percentage) of the pellets produced. This was true also for samples C (1:1 
Gly:PVP VA64) and D (1:2 Gly:PVP VA64). The porosity values for samples C and D were 
19.47 % and 14.22 % respectively suggesting also that an increase in polymer content 
decreases the porosity of pellets produced. The porosity of all the samples were thus in the 
following order: A > B > C > D. These results suggest that the PVP VA64 makes denser 
pellets which may well have dissolution consequences.  
 
3.4. Contact angle measurement 
Contact angle measurements performed using deionised water initially showed sample A (1:1 
Gly:Sol) to have the highest contact angle (90.65 ± 7.06 °). This was followed closely by 
sample B (1:2 Gly:Sol) with a contact angle of 84.41 ± 2.60 °. Sample C had the lowest 
contact angle (33.72 ± 1.24 °) followed by sample D with an angle of 41.11 ± 2.33 ° (Figure 
8). This suggested samples C and D to be significantly more hydrophilic than samples A and 
B. Dynamic contact angle measurements for the samples using FASSIF proved surprising 
and interesting. The contact angles for samples A (1:1 Gly:Sol) and B (1:2 Gly:Sol) could not 
be obtained as the droplet absorbed very quickly (within a few seconds). As such, the elapsed 
time for the droplet to be absorbed for these samples were taken into consideration.  The 
mean time for sample A to be absorbed was 1.67 ± 0.50 s, whereas the mean time for sample 
B to be absorbed was 0.17 ± 0.05 s. This indicates that sample B wets slightly better than 
sample A. This was in direct contrast to the results from deionised water suggesting that the 
presence of the various ions in the FASSIF media may have had a solubilising effect on the 
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samples with an increase in polymer content having a greater effect. Samples C (1:1 Gly:PVP 
VA64)  and D (1:2 Gly:PVP VA64) however had a lower absorption rate compared to 
samples A and B therefore the dynamic contact angle (Figure 9) could be determined. The 
data reveals that even though the initial contact angles for samples C and D were similar, 
sample D wets better than sample C over time. This was also similar to the trend observed for 
samples A and B where an increase in polymer content seemed to accelerate the ingress of 
media.  In summary, the order of wetting for samples was: B > A > D > C. This change in 
contact angle order in comparison with deionised water may have implications again for 
dissolution testing and as such consideration should be made with regards to making 
appropriate predictions for dissolution based on the media for contact angle testing.  
3.5. Dissolution analysis 
Results of dissolution testing for capsules filled with the milled and sieved powders are 
presented in Figure 10. The physical mixtures displayed dissolution profiles similar to that of 
the pure crystalline drug whereas the HME samples displayed dissolution profiles superior to 
that of the crystalline drug and the physical mixtures. It was also observed from the 
dissolution profiles that samples containing Sol had higher dissolution rates in comparison 
with samples that contained PVP VA64. Furthermore, sample B, which contained 1:2 
Gly:Sol, showed a higher dissolution rate in comparison to sample A (1:1 Gly:Sol). This 
indicates that increasing the level of polymer content increased the dissolution of Gly. A 
similar trend was observed with sample C and D, with sample D (1:2 Gly:PVP VA64) 
showing a higher dissolution rate in comparison to sample C (1:1 Gly:PVP VA64). This was 
confirmed by the MDT, MDR and DE values. Sample A had a DE value of 36.43 %, MDT of 
55.40 min and an MDR of 0.51 % min
−1
 while sample B had a DE of 60.53 %, MDT of 29.70 
min and MDR of 0.91 % min
−1
. Sample C had a DE value of 10.17 %, MDT of 66.28 min 
and MDR of 0.14 % min
−1
 while sample D had a value of DE of 14.44 %, MDT of 65.30 min 
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and MDR of 0.19 % min
−1
. It was interesting to note that the dissolution results correlated 
with the wetting results from the contact angle measurement using the FASSIF media. This 
indicates that the initial liquid imbibition process as captured by the dynamic contact angle 
directly affects the dissolution performance. The authors attribute the dissolution 
behaviour to the nature of the polymers, its concentration as well as the degree of 
amorphorisation (it can be observed from figure 4 that Gly is more molecularly 
dispersed in Sol than in the PVP VA64. This contributed to its increase in wettability as 
well as dissolution with sample B (higher in amorphous content) being the one with the 
highest dissolution). This is because the particle sizes of the formulation were controlled 
(< 250 µm) and further confirmed using laser diffraction (Supplementary material 
Table S2). 
4. CONCLUSIONS 
Solid dispersion of Gly with Sol and PVP VA64 were made at varying concentrations using 
hot-melt extrusion. The solid dispersions were successfully characterised using a range of 
techniques. SEM and focus variation analysis showed differences in the microstructure and 
surface morphology of the samples produced which could be attributed to the level of 
polymer content present within them. XµT showed an increase in polymer content brought 
about a decrease in porosity of the hot-melt extruded dispersions with PVP VA64 potentially 
making denser products which could have its own implications. The static and dynamic 
contact angle measurement correlated with the dissolution studies using FASSIF media 
indicating that the initial liquid imbibition process as captured by the dynamic contact angle 
directly affects the dissolution performance which is of great importance as this techniques 
could be exploited in predicting dissolution performance.  
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Figure captions 
Figure 1. Structure of Glyburide, Soluplus
®
 and Kollidon
®
 PVP VA64 used in the 
manufacture of pellets from the hot-melt extrusion process for the formulations (Samples A-
D) 
Figure 2. Contact angle testing instrumentation used in the study to determine the wettability 
and initial liquid imbibition of the solid dispersions produced  
Figure 3. DSC thermograms of (A) crystalline Gly, the physical mixtures of (B) 1:1 Gly:Sol, 
(C) 1:2 Gly:Sol, (D) 1:1 Gly:PVP VA64, (E) 1:2 Gly:PVP VA64, and the hot-melt extruded 
samples of (F) 1:1 Gly:Sol, (G) 1:2 Gly:Sol,  (H)1:1 Gly:PVP VA64 , (I) 1:2 Gly:PVP VA64.  
Figure 4. XRD of (A) crystalline Gly, the physical mixtures of (B) 1:1 Gly: Sol , (C) 1:2 Gly: 
Sol, (D) 1:1 Gly:PVP VA64, (E) 1:2 Gly:PVP VA64, and the hot-melt extruded samples of 
(F) 1:1 Gly:Sol, (G) 1:2 Gly:Sol,  (H)1:1 Gly:PVP VA64 , (I) 1:2 Gly:PVP VA64. 
Figure 5. SEM images of Gly, (A) HME extrudate pellets of 1:1 Gly:Sol (sample A) 
formulation, (A1) physical mixture of 1:1 Gly:Sol, (A2) 1:1 Gly:Sol (milled and sieved 
sample from HME extrude pellets of A), (B) HME extrudate pellets of 1:2 Gly:Sol (sample 
B) formulation, (B1) physical mixture of 1:2 Gly:Sol, (B2) 1:2 Gly:Sol (milled and sieved 
sample from HME extrude pellets of B), (C) HME extrudate pellets of 1:1 Gly:PVP VA64 
(sample C) formulation (C1) physical mixture of 1:1 Gly:PVP VA64 (C2) 1:1 Gly:PVP 
VA64 (milled and sieved sample from HME extrude pellets of C), (D) HME extrudate of 1:2 
Gly:PVP VA64 (sample D) formulation, (D1) physical mixture of 1:2 Gly:PVP VA64 (D2) 
1:2 Gly:PVP VA64 (milled and sieved sample from HME extrude pellets of D). 
Figure 6. Focus variation images of (A) HME extrudate pellet of 1:1 Gly:Sol (sample A) 
formulation, (B) HME extrudate pellet of 1:2 Gly:Sol (sample B) formulation, (C) HME 
extrudate pellet of 1:1 Gly:PVP VA64 (sample C) formulation, (D) HME extrudate pellet of 
1:2 Gly:PVP VA64 (sample D) formulation. 
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Figure 7. XμT of sagittal and diametric images of formulated HME extrudate pellet (A) 
HME extrudate pellet of 1:1 Gly:Sol (sample A),  (B) HME extrudate pellet of 1:2 Gly:Sol 
(Sample B), (C) HME extrudate pellet of 1:1 Gly:PVP VA64 (sample C), (D) HME extrudate 
pellet of 1:2 Gly:PVP VA64 (sample D). 
Note: Colour code for density histogram: Figure 7A-D, red colour is Gly, green and blue 
colour are polymer (Sol or PVP VA64) and black represents the pores 
Figure 8. Contact angle testing of (A) 1:1 Gly:Sol (sample A),  (B) 1:2 Gly:Sol (Sample B), 
(C) 1:1 Gly:PVP VA64 (Sample C), (D) 1:2 Gly:PVP VA64 (Sample D) and (E) a plot of all 
the contact angle degrees of samples A-D for comparison. 
Figure 9. Dynamic contact angle measurement of samples C (1:1 Gly:PVP VA64) and D 
(1:2 Gly:PVP VA64)  using FASSIF as the media 
Figure 10. Dissolution profiles for 1:1 Gly:Sol (sample A),  1:2 Gly:Sol (Sample B), 1:1 
Gly:PVP VA64 (Sample C), 1:2 Gly:PVP VA64 (Sample D) together with their 
corresponding physical mixtures PMA-PMD over 120 min 
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Figure 2. 
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Figure 3. 
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Figure 4. 
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Figure 5. 
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Figure 6. 
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Figure 7. 
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Figure 8. 
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Figure 9. 
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Figure 10. 
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Highlights 
1. Solid dispersions of glyburide made by hot-melt extrusion 
2. SEM and focus variation analysis showed microstructure and surface morphology was 
significantly different between samples  
3. XµT showed that an increase in polymer content brought about a decrease in porosity 
4. Static and dynamic contact angle measurement correlated with the dissolution studies 
using FASSIF media 
5. Results show the initial liquid imbibition process captured by the dynamic contact angle 
directly affects the dissolution performance 
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Graphical Abstract 
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